Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing ...

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgen’s bone cancer drug XGEVA, used to ...

Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.

Despite these positive clinical developments, Amgen and Viking Therapeutics have performed poorly on the stock market in the past 12 months, though progress in this area might eventually help them ...